不可切除胰腺癌五分割立体定向磁共振引导在线自适应放疗的多中心2期试验
这项多中心单臂2期试验纳入136例局部晚期或交界可切除胰腺癌患者,在≥3个月系统治疗后给予50 Gy/5次磁共振引导在线自适应放疗。主要终点为明确归因于该治疗的急性≥3级胃肠道毒性,结果为0例;可能或很可能归因的急性≥3级胃肠道毒性发生率为8.8%,包括2例术后死亡。
要点
- 50 Gy/5次磁共振引导在线自适应放疗未出现明确归因的急性≥3级胃肠道毒性。
- 可能或很可能归因的急性≥3级胃肠道毒性发生率为8.8%,含2例术后死亡。
- 作者建议该治疗后手术尤其血管切除时应谨慎。
核心结论
- 主要终点达到,无明确归因于50 Gy/5次立体定向磁共振引导在线自适应放疗的急性≥3级胃肠道毒性。
- 尚不清楚该治疗是否导致术后毒性,作者建议后续手术尤其血管切除时应谨慎。
- 正在继续随访以评估晚期毒性、生活质量和长期疗效。
研究设计与样本
- 多中心、单臂、2期试验,纳入局部晚期或交界可切除胰腺癌患者,要求系统治疗≥3个月且无远处进展证据。
- 共136例患者于2019年1月至2022年1月入组,局部晚期56.6%、交界可切除43.4%。
- 处方剂量为50 Gy分5次,在0.35T磁共振引导放疗系统上实施。
- 主要终点为明确归因于该治疗的急性≥3级胃肠道毒性。
主要发现
- 平均年龄65.7岁(范围36-85岁),胰头病变最常见(66.9%)。
- 诱导化疗主要为(改良)FOLFIRINOX(65.4%)或吉西他滨/白蛋白结合型紫杉醇(16.9%)。
- 诱导化疗后、该治疗前平均CA19-9为71.7 U/mL(范围0-468)。
- 所有已实施分次中93.1%进行了在线自适应再计划。
- 可能或很可能归因于该治疗的急性≥3级胃肠道毒性发生率为8.8%,包括2例术后死亡(可能与该治疗相关)。
关键数值与推荐
- 主要终点:明确归因于该治疗的急性≥3级胃肠道毒性为0例。
- 可能或很可能归因的急性≥3级胃肠道毒性发生率为8.8%。
- 自该治疗起1年总生存率为65.0%。
- 自诊断和自该治疗起中位随访分别为16.4个月和8.8个月。
临床怎么用
- 作者建议该治疗后手术尤其血管切除时应谨慎。
- 原文未据此给出其他推荐。
局限性
- 尚不清楚该治疗是否导致术后毒性。
- 需要继续随访以评估晚期毒性、生活质量和长期疗效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Magnetic resonance (MR) image guidance may facilitate safe ultrahypofractionated radiation dose escalation for inoperable pancreatic ductal adenocarcinoma. We conducted a prospective study evaluating the safety of 5-fraction Stereotactic MR-guided on-table Adaptive Radiation Therapy (SMART) for locally advanced (LAPC) and borderline resectable pancreatic cancer (BRPC). METHODS AND MATERIALS: Patients with LAPC or BRPC were eligible for this multi-institutional, single-arm, phase 2 trial after ≥3 months of systemic therapy without evidence of distant progression. Fifty gray in 5 fractions was prescribed on a 0.35T MR-guided radiation delivery system. The primary endpoint was acute grade ≥3 gastrointestinal (GI) toxicity definitely attributed to SMART. RESULTS: One hundred thirty-six patients (LAPC 56.6%, BRPC 43.4%) were enrolled between January 2019 and January 2022. Mean age was 65.7 (36-85) years. Head of pancreas lesions were most common (66.9%). Induction chemotherapy mostly consisted of (modified)FOLFIRINOX (65.4%) or gemcitabine/nab-paclitaxel (16.9%). Mean CA19-9 after induction chemotherapy and before SMART was 71.7 U/mL (0-468). On-table adaptive replanning was performed for 93.1% of all delivered fractions. Median follow-up from diagnosis and SMART was 16.4 and 8.8 months, respectively. The incidence of acute grade ≥3 GI toxicity possibly or probably attributed to SMART was 8.8%, including 2 postoperative deaths that were possibly related to SMART in patients who had surgery. There was no acute grade ≥3 GI toxicity definitely related to SMART. One-year overall survival from SMART was 65.0%. CONCLUSIONS: The primary endpoint of this study was met with no acute grade ≥3 GI toxicity definitely attributed to ablative 5-fraction SMART. Although it is unclear whether SMART contributed to postoperative toxicity, we recommend caution when pursuing surgery, especially with vascular resection after SMART. Additional follow-up is ongoing to evaluate late toxicity, quality of life, and long-term efficacy.
引用
- Parikh PJ, Lee P, Low DA, et al. A Multi-Institutional Phase 2 Trial of Ablative 5-Fraction Stereotactic Magnetic Resonance-Guided On-Table Adaptive Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Cancer. Int J Radiat Oncol Biol Phys. 2023. PMID: 37210048. doi:10.1016/j.ijrobp.2023.05.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。